Use of opioids in the long term leads to shorter length of stay (LOS) and reduced inpatient mortality among patients hospitalized with nonmetastatic colorectal cancer (CRC), results of a study have shown. However, patients with cancer-related complications endure longer LOS and higher mortality than those admitted without such morbidities.
A novel combination of celecoxib and Myrtol for recurrent appendiceal mucinous neoplasma (AMN) with extensive peritoneal dissemination is well tolerated and appears to extend progression-free (PFS) and overall survival (OS) in patients, a recent study has found.
The time elapsed between diagnosis of rectal cancer and initiation of neoadjuvant chemoradiation (NCRT) shows a significant association with pathologic complete response (pCR), and shortening this time may improve the likelihood of achieving pCR, suggests a recent study.
Magnetic resonance imaging (MRI)-targeted biopsy misses of clinically significant cancers seldom occur, but such rare cases are mostly caused by errors in lesion targeting, which underscores the importance of accurate coregistration and targeting when using software-based fusion platforms, according to a study. Moreover, some patients harbor MRI-invisible lesions, which cannot be targeted by MRI platforms.
In a phase II study, the novel oral HIF*-2α inhibitor belzutifan showed promise for individuals with renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease, a rare autosomal dominant hereditary disease associated with benign and malignant neoplasms, including clear-cell RCC, pancreatic neuroendocrine tumours, and CNS** and retinal hemangioblastomas.
The combination of cabozantinib and atezolizumab in the first-line setting significantly improved progression-free survival (PFS) compared with sorafenib in patients with advanced hepatocellular carcinoma (HCC), according to results of the phase III COSMIC-312 trial presented at ESMO Asia 2021.
Induction with ixazomib-based regimens appear to be insufficient for older patients newly diagnosed multiple myeloma who are ineligible for transplantation, achieving an unsatisfactory progression-free survival (PFS) rate, reports a recent study.